Urine-Derived Exosomes (USC-Exos)

Preclinical

Urine-Derived Exosomes (USC-Exos) is one of 2 therapeutic programs targeting Erectile Dysfunction Following Radical Prostatectomy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Erectile Dysfunction Following Radical ProstatectomyNot yet recruiting

Erectile Dysfunction Following Radical ProstatectomyPreclinical

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Erectile Dysfunction Following Radical Prostatectomy

#DrugCompanyPhaseTrials

Cialis

Eli Lilly

Phase 2

1 2

Urine-Derived Exosomes (USC-Exos)

MMedipol University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalNot yet recruiting

Erectile Dysfunction Following Radical Prostatectomy

NCT07707505

Clinical

Trials by Indication[1]

Erectile Dysfunction Following Radical Prostatectomy1 trial

Intracavernosal Exosomes Versus Rectal Ozone Therapy for Erectile Dysfunction Following Robotic-Assisted Radical Prostatectomy

Not yet recruiting·MMedipol University·Preclinical·NCT07707505·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Urine-Derived Exosomes (USC-Exos). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Urine-Derived Exosomes (USC-Exos). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Medipol University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: MMedipol University

Urine-Derived Exosomes (USC-Exos)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Erectile Dysfunction Following Radical Prostatectomy1 trial

References

Drug Info

Quick Facts

Related News